1Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada
3Obstetrics & Gynaecology, Mount Sinai Hospital, Toronto, Ontario, Canada
4Obstetrics & Gynaecology, Lakeshore General Hospital, Montreal, Quebec, Canada
5Department of Obstetrics and Gynaecology, McGill University, Montreal, Quebec, Canada
6Obstetrics and Gynaecology, CIUSSS-de-l’Est-de-l’Île-de-Montréal, Montreal, Quebec, Canada
7Department of Obstetrics and Gynaecology, Université de Montréal, Montreal, Quebec, Canada
8Obstetrics & Gynaecology, St. Michael's Hospital, Toronto, Ontario, Canada.
Address correspondence to: Marie K. Christakis, MD, MPH, FRCSC, NCMP, 61 Queen Street East—5th Floor; Toronto, M5C 2T2, ON, Canada. E-mail: [email protected]
Received 1 May, 2021
Revised 15 July, 2021
Accepted 15 July, 2021
Funding/support: This work was funded by a New Investigator Grant provided to M.K.C. by the St. Michael's Hospital Department of Obstetrics & Gynaecology.
Financial disclosure/conflicts of interest: F.M.: None; L.S.: None; L.N.H.: Advisory Board for Byosent (Tibella), Pfizer; M.J.: Pfizer, Biosyent, Duchesnay; R.J.: Speaker and Advisory Board consultant for BioSyent and Pfizer; M.K.C.: None.
Meeting Presentation: This manuscript has been presented as a poster abstract titled “Quality and readability of publicly accessible information on menopausal hormone replacement therapy in Canada: What are our patients reading?” at the Society of Obstetricians and Gynaecologists of Canada Annual Clinical and Scientific Conference in June 2021 (Online)
Supplemental digital content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's Website (www.menopause.org)
